ArteraAI Breast Gains FDA Clearance for Cancer Risk
SAN FRANCISCO, May 6, 2026 Artera announced that the U.S. Food and Drug Administration (FDA) has granted clearance for...
Obesity treatment
Advertisement
GSK Signs $1B SiranBio siRNA Cardiometabolic Deal
SUZHOU, China, May 6, 2026 SiranBio announced a major global licensing agreement with GSK for its investigational siRNA therapeutic...
Boehringer Survodutide Shows 16.6% Weight Loss in Phase III
INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...
Anaxiom AVOS Device Shows Safe Early Obesity Results
LAGUNA HILLS, Calif., April 2026 Anaxiom Corporation has announced encouraging early clinical results from its first-in-human study of the...
Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Advertisements
Insilico Medicine Advances ISM6200 for Cancer Therapy
HONG KONG | April 10, 2026 Insilico Medicine has announced the nomination of ISM6200, a potential best-in-class selective NR3C1...
Lilly Launches Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayo™ (orforglipron), a first-in-class oral...
FDA Approves Lilly Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
FDA Approves Rhythm Pharmaceuticals’ IMCIVREE for Acquired Hypothalamic Obesity
BOSTON, March 19, 2026 Rhythm Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Imcivree (setmelanotide) for...
Advertisement
